Nanoviricides Stock Performance
| NNVC Stock | USD 1.15 0.03 2.54% |
The company secures a Beta (Market Risk) of 0.35, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, NanoViricides' returns are expected to increase less than the market. However, during the bear market, the loss of holding NanoViricides is expected to be smaller as well. At this point, NanoViricides has a negative expected return of -0.34%. Please make sure to verify NanoViricides' potential upside, as well as the relationship between the daily balance of power and market facilitation index , to decide if NanoViricides performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days NanoViricides has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain rather sound which may send shares a bit higher in February 2026. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders. ...more
| Begin Period Cash Flow | 4.8 M | |
| Total Cashflows From Investing Activities | -57 K |
NanoViricides | Build AI portfolio with NanoViricides Stock |
NanoViricides Relative Risk vs. Return Landscape
If you would invest 161.00 in NanoViricides on October 27, 2025 and sell it today you would lose (46.00) from holding NanoViricides or give up 28.57% of portfolio value over 90 days. NanoViricides is currently does not generate positive expected returns and assumes 6.525% risk (volatility on return distribution) over the 90 days horizon. In different words, 58% of stocks are less volatile than NanoViricides, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
NanoViricides Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for NanoViricides' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as NanoViricides, and traders can use it to determine the average amount a NanoViricides' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Based on monthly moving average NanoViricides is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of NanoViricides by adding NanoViricides to a well-diversified portfolio.
NanoViricides Fundamentals Growth
NanoViricides Stock prices reflect investors' perceptions of the future prospects and financial health of NanoViricides, and NanoViricides fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on NanoViricides Stock performance.
| Return On Equity | -0.94 | ||||
| Return On Asset | -0.51 | ||||
| Current Valuation | 23.68 M | ||||
| Shares Outstanding | 21.57 M | ||||
| Price To Earning | (6.02) X | ||||
| Price To Book | 3.46 X | ||||
| EBITDA | (8.72 M) | ||||
| Cash And Equivalents | 14.07 M | ||||
| Cash Per Share | 1.21 X | ||||
| Total Debt | 1.31 M | ||||
| Debt To Equity | 0 % | ||||
| Book Value Per Share | 0.41 X | ||||
| Cash Flow From Operations | (8.48 M) | ||||
| Earnings Per Share | (0.50) X | ||||
| Total Asset | 8.82 M | ||||
| Retained Earnings | (148.84 M) | ||||
| Current Asset | 24.38 M | ||||
| Current Liabilities | 6.74 M | ||||
About NanoViricides Performance
By analyzing NanoViricides' fundamental ratios, stakeholders can gain valuable insights into NanoViricides' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if NanoViricides has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if NanoViricides has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
NanoViricides, Inc., a nano-biopharmaceutical research and development company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company was founded in 2005 and is based in Shelton, Connecticut. Nanoviricides operates under Biotechnology classification in the United States and is traded on AMEX Exchange. It employs 17 people.Things to note about NanoViricides performance evaluation
Checking the ongoing alerts about NanoViricides for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for NanoViricides help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| NanoViricides generated a negative expected return over the last 90 days | |
| NanoViricides has high historical volatility and very poor performance | |
| NanoViricides may become a speculative penny stock | |
| NanoViricides has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (9.47 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| NanoViricides currently holds about 14.07 M in cash with (8.48 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.21, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
- Analyzing NanoViricides' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether NanoViricides' stock is overvalued or undervalued compared to its peers.
- Examining NanoViricides' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating NanoViricides' management team can have a significant impact on its success or failure. Reviewing the track record and experience of NanoViricides' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of NanoViricides' stock. These opinions can provide insight into NanoViricides' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for NanoViricides Stock analysis
When running NanoViricides' price analysis, check to measure NanoViricides' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NanoViricides is operating at the current time. Most of NanoViricides' value examination focuses on studying past and present price action to predict the probability of NanoViricides' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NanoViricides' price. Additionally, you may evaluate how the addition of NanoViricides to your portfolios can decrease your overall portfolio volatility.
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years |